CytomX Therapeutics (CTMX) Operating Leases (2019 - 2026)
CytomX Therapeutics' (CTMX) quarterly Operating Leases came in at $1.4 million in Q2 2025, down 79.06% YoY from $6.9 million in Q2 2024, and down 49.51% on a QoQ basis from $2.9 million in Q1 2025.
CytomX Therapeutics (CTMX) Operating Leases (2019 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 7 years of Operating Leases data on file, last reported at $1.4 million in Q2 2025.
- Quarterly Operating Leases fell 79.06% year-over-year to $1.4 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.4 million (down 79.06% YoY) and the FY2024 annual result came in at $4.2 million, down 54.82% from the prior year.
- Operating Leases declined to $1.4 million in Q2 2025, from $2.9 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $20.8 million in Q1 2021 to a low of $1.4 million in Q2 2025.
- A 5-year average of $11.9 million and a median of $12.3 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2021 — Operating Leases decreased 13.68% — and 2025, when it plunged 79.06%.
- Tracing CTMX's Operating Leases over 5 years: stood at $18.1 million in 2021, then retreated by 22.6% to $14.0 million in 2022, then sank by 32.84% to $9.4 million in 2023, then plunged by 54.82% to $4.2 million in 2024, then plunged by 65.99% to $1.4 million in 2025.
- The last three Operating Leases figures came in at $1.4 million (Q2 2025), $2.9 million (Q1 2025), and $4.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.21 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 4.24 Mn |
| Sep 30, 2024 | 5.60 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 8.15 Mn |
| Dec 31, 2023 | 9.39 Mn |
| Sep 30, 2023 | 10.60 Mn |
| Jun 30, 2023 | 11.75 Mn |
| Mar 31, 2023 | 12.87 Mn |
| Dec 31, 2022 | 13.98 Mn |
| Sep 30, 2022 | 15.06 Mn |
| Jun 30, 2022 | 16.08 Mn |
| Mar 31, 2022 | 17.08 Mn |
| Dec 31, 2021 | 18.06 Mn |
| Sep 30, 2021 | 19.02 Mn |
| Jun 30, 2021 | 19.92 Mn |
| Mar 31, 2021 | 20.81 Mn |
| Dec 31, 2020 | 21.68 Mn |